NEW YORK, August 1, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Investors' Reports announced new research reports
highlighting Quest Diagnostics Incorporated (NYSE: DGX),
PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation
(NASDAQ: PRXL), Covance Inc. (NYSE: CVD), and ICON plc (NASDAQ:
ICLR). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings
- via the links below.
Quest Diagnostics Incorporated
Research Report
On July 18, 2013, Quest
Diagnostics Incorporated (Quest Diagnostics) reported its Q2 2013
financial results. Q2 2013 adjusted income from continuing
operations came in at $164 million,
or $1.06 per diluted share, compared
to $185 million, or $1.15 per diluted share, in Q2 2012. Q2 2013
revenues from continuing operations were $1.8 billion, down 3.3% YoY. Commenting on the
results, Steve Rusckowski, President
and CEO of Quest Diagnostics, said, "As expected, revenues and
earnings improved from first quarter levels, but were down versus
the prior year. We saw continued revenue softness in the second
quarter compared to the prior year due to lower healthcare
utilization and reductions in reimbursement." He added, "We lowered
our full-year revenue guidance to reflect softer healthcare
utilization." For full-year 2013, the Company now expects revenues
to be down 1% to 2% YoY, compared to its previous guidance of
approximating full-year 2012 level. The Full Research Report on
Quest Diagnostics Incorporated - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.investorsreports.com/report/2013-07-30/DGX]
--
PerkinElmer, Inc. Research Report
On July 26, 2013, PerkinElmer,
Inc. (PerkinElmer) announced that its Board of Directors has
declared a regular quarterly dividend of $0.07 per share of common stock. PerkinElmer
reported that the dividends will be payable on November 8, 2013, to shareholders of record at
the close of business on October 18,
2013. The Full Research Report on PerkinElmer, Inc. -
including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/PKI]
--
PAREXEL International Corporation
Research Report
On July 10, 2013, PAREXEL
International Corporation (PAREXEL) announced that it will present
its Q4 FY 2013 and full-year FY 2013 financial results on
August 7, 2013, after the close of
the stock market. The Company will host a conference call and a
live webcast on August 8, 2013 at
10:00 a.m. ET to discuss the results.
The Full Research Report on PAREXEL International Corporation -
including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/PRXL]
--
Covance Inc. Research Report
On July 29, 2013, Covance Inc.
(Covance) announced that its central laboratory services once again
ranked first in an independent global survey of physician
investigators participating in clinical trials, the Clinical
Trial Investigator Satisfaction and Central Laboratory
Performance survey. Covance informed that the survey was
conducted in June and July 2013 by
the Life Science Strategy Group, and in the survey, 47% of the
study participants named Covance's central laboratory services as
their most preferred central laboratory, with investigators citing
Covance more than twice as often the nearest competitor. Further,
investigators also reported having the best overall relationship
with the Company, rating it 8.4 on a scale of 1 to 10. "This study
demonstrates that investigators around the world continue to
recognize and value Covance's services and benefit from our decades
of experience and extensive testing capabilities," said
Jon Koch, Corporate Vice President
and Global General Manager of Central Laboratory Services at
Covance. The Full Research Report on Covance Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/CVD]
--
ICON plc Research Report
On July 25, 2013, ICON plc (ICON)
reported its Q2 2013 financial results. Q2 2013 net revenue
increased 20.7% YoY to $334.2
million. Net income for Q2 2013, excluding restructuring
charges, was $26.5 million, or
$0.43 per diluted share, compared
with $12.9 million, or $0.21 per diluted share in Q2 2012. Commenting on
the results, the Company's CEO Ciaran
Murray said, "I am happy that Q2 was another strong quarter
for ICON. We reported revenue growth of 21% year on year and
operating margins of 9.3%. We have continued to book satisfactory
levels of new business and our trailing twelve month book to bill
now stands at 1.3. Consequently we are raising our revenue guidance
to the range of $1.3-$1.32 billion
and our EPS guidance to the range of $1.54-$1.64 for the financial year 2013." The
Full Research Report on ICON plc - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/ICLR]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
http://InvestorsReports.com
SOURCE Investors' Reports